Annual Report 2021

Operating Activities

(9) Net sales

Accounting and measurement policies

Nature and timing of revenue recognition

Net sales are recognized when (or as) the customer obtains control of the asset. For sales of goods, the customer typically obtains control as soon as delivery is made, given that the customer is generally not able to obtain any benefits from the asset before that point in time. In the case of equipment sales, the criteria for revenue recognition are only met after installation has been successfully completed – to the extent that the installation requires specialized knowledge, does not represent a clear ancillary service and the relevant equipment can only be used by the customer once successfully set up.

For service contracts and customer-specific contract manufacturing of goods and equipment, the Group recognizes revenue over time based on the progress towards complete satisfaction of the performance obligation, if there is a contractual claim for payment against the customer for the services already performed. Input- and output-oriented methods are used to appropriately determine progress on a contract-specific basis. Specifically, they are mainly calculated on the basis of the time elapsed, milestones reached, units delivered, or costs incurred as of the reporting date.

Intellectual property is out-licensed to a limited extent in the Life Science and Healthcare business sectors. Unlike in the Life Science business sector, these transactions do not usually form part of ordinary activities in the Healthcare business sector, meaning that the corresponding income is reported in other operating income (see Note (7) “Collaboration and licensing agreements” and Note (13) “Other operating income”).

Net sales from contracts comprising several separate performance obligations are recognized on a pro rata basis when the respective performance obligation has been fulfilled. Multiple-element arrangements of this nature exist to a limited extent in the Applied Solutions business unit in the Life Science business sector and in the Semiconductor Solutions business unit in the Electronics business sector.

Determining the transaction price

The Group grants customers various kinds of rebates and discounts. These, as well as anticipated customer refund claims, state compulsory charges and rebates from health plans and programs, are deducted from sales. The most significant portion of these deductions from sales is attributable to the Healthcare business sector and, in particular, sales in the United States.

Sales deductions provided on the invoice as price-reducing items, which will likely be applied by customers when making the respective payments, are recognized as reduction of trade accounts receivable. Expected refunds, such as bonus payments, reimbursements for rights of return or rebates from health plans and programs, are reported in the consolidated balance sheet under refund liabilities.

The measurement of sales deductions and refund liabilities resulting from expected rebates and discounts considers the following:

  • past experience;
  • pricing information;
  • expected sales volume growth rates.

The measurement of sales deductions and refund liabilities resulting from rights of return takes into account historical rates of return for individual product groups, information from distributors on inventory levels and publicly available information on product sales from sector-specific service providers (in the Healthcare business sector).

Contractual payment terms

Given that the Group generates the large majority of its net sales through transactions with simple structures, the company usually has an enforceable right to payment after the performance obligation has been fulfilled. The payment targets contractually agreed between the Group and its customers usually range between 30 and 60 days.

Practical expedients

The Group uses the practical expedient of IFRS 15 in which the promised amount of consideration is not adjusted for the effects of a significant financing component if the period between the fulfillment of a performance obligation and the payment by the customer only amounts to up to one year.

Significant discretionary decisions and sources of estimation uncertainty

Sales deductions

The measurement of sales deductions and the corresponding refund liabilities requires extensive estimates. Uncertainties exist in particular concerning the extent to which past experience serves as a reliable basis for estimating the future development of expected refunds, such as bonus payments, reimbursements for rights of return or rebates from health plans and programs. External information from distributors and industry services outside of the Group’s control, which are also subject to uncertainty, are used to determine sales deductions.

Due to a lack of past experience, the estimation uncertainty referenced above is particularly relevant for product launches in the Healthcare business sector.

Any changes in estimates of the parameters listed above have a cumulative impact on the net sales for the respective adjustment period.

If the carrying amount of refund liabilities had been 10% higher as of the reporting date, this would have resulted in a € 84 million (2020: € 67 million) reduction in profit before tax.

The following tables present a breakdown of net sales by key product lines/products:

Life Science

€ million

 

2021

 

20201

Process Solutions

 

4,645

 

52%

 

3,595

 

48%

Research Solutions

 

2,512

 

28%

 

2,215

 

29%

Applied Solutions

 

1,833

 

20%

 

1,705

 

23%

Total

 

8,990

 

100%

 

7,515

 

100%

1

Previous year’s figures have been adjusted due to an internal realignment.

Healthcare

€ million

 

2021

 

2020

Oncology

 

1,411

 

20%

 

1,116

 

17%

thereof: Erbitux®

 

987

 

14%

 

891

 

13%

thereof: Bavencio®

 

373

 

5%

 

156

 

2%

Neurology & Immunology

 

1,645

 

23%

 

1,662

 

25%

thereof: Rebif®

 

952

 

13%

 

1,131

 

17%

thereof: Mavenclad®

 

693

 

10%

 

531

 

8%

Fertility

 

1,337

 

19%

 

1,079

 

16%

thereof: Gonal-f®

 

767

 

11%

 

630

 

9%

Cardiovascular, Metabolism & Endocrinology

 

2,540

 

36%

 

2,585

 

39%

thereof: Glucophage®

 

864

 

12%

 

903

 

14%

thereof: Concor®

 

523

 

7%

 

529

 

8%

thereof: Euthyrox®

 

470

 

7%

 

455

 

7%

thereof: Saizen®

 

248

 

3%

 

234

 

4%

Other

 

157

 

2%

 

197

 

3%

Total

 

7,089

 

100%

 

6,639

 

100%

Electronics

€ million

 

2021

 

20201

Semiconductor Solutions

 

2,151

 

60%

 

1,894

 

56%

Display Solutions

 

1,046

 

29%

 

1,115

 

33%

Surface Solutions

 

410

 

11%

 

370

 

11%

Other

 

 

 

1

 

Total

 

3,608

 

100%

 

3,380

 

100%

1

Within the scope of the integration of Versum Materials Inc., USA, two products previously allocated to the Semiconductor Solutions business unit have now been assigned to Display Solutions. The previous year’s figures have been adjusted accordingly.

The following tables present a more detailed breakdown of net sales by business sector from contracts with customers.

2021

€ million

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by product type

 

Life Science

 

Healthcare

 

Electronics

 

Group

Goods

 

7,906

 

88%

 

7,011

 

99%

 

3,182

 

88%

 

18,099

 

92%

Equipment

 

469

 

5%

 

2

 

 

336

 

9%

 

807

 

4%

Services

 

603

 

7%

 

26

 

 

88

 

3%

 

718

 

4%

License income

 

12

 

 

 

 

1

 

 

14

 

Commission income

 

 

 

18

 

 

 

 

18

 

Income from co-commercialization agreements

 

 

 

31

 

1%

 

 

 

31

 

Total

 

8,990

 

100%

 

7,089

 

100%

 

3,608

 

100%

 

19,687

 

100%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by region
(customer location)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Europe

 

3,138

 

35%

 

2,268

 

32%

 

269

 

7%

 

5,675

 

29%

North America

 

3,187

 

36%

 

1,673

 

23%

 

536

 

15%

 

5,397

 

27%

Asia-Pacific

 

2,286

 

25%

 

1,997

 

28%

 

2,737

 

76%

 

7,020

 

36%

Latin America

 

278

 

3%

 

682

 

10%

 

30

 

1%

 

990

 

5%

Middle East and Africa

 

100

 

1%

 

468

 

7%

 

36

 

1%

 

605

 

3%

Total

 

8,990

 

100%

 

7,089

 

100%

 

3,608

 

100%

 

19,687

 

100%

2020

€ million

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by product type

 

Life Science

 

Healthcare

 

Electronics

 

Group

Goods

 

6,585

 

88%

 

6,496

 

98%

 

3,029

 

90%

 

16,111

 

92%

Equipment

 

386

 

5%

 

5

 

 

254

 

7%

 

645

 

4%

Services

 

535

 

7%

 

56

 

1%

 

96

 

3%

 

686

 

4%

License income

 

9

 

 

 

 

1

 

 

10

 

Commission income

 

 

 

18

 

 

 

 

18

 

Income from co-commercialization agreements

 

 

 

65

 

1%

 

 

 

65

 

Total

 

7,515

 

100%

 

6,639

 

100%

 

3,380

 

100%

 

17,534

 

100%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by region (customer location)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Europe

 

2,583

 

35%

 

2,158

 

32%

 

250

 

8%

 

4,991

 

29%

North America

 

2,701

 

36%

 

1,554

 

23%

 

484

 

14%

 

4,739

 

27%

Asia-Pacific

 

1,900

 

25%

 

1,831

 

28%

 

2,582

 

76%

 

6,313

 

36%

Latin America

 

241

 

3%

 

641

 

10%

 

28

 

1%

 

910

 

5%

Middle East and Africa

 

89

 

1%

 

455

 

7%

 

37

 

1%

 

581

 

3%

Total

 

7,515

 

100%

 

6,639

 

100%

 

3,380

 

100%

 

17,534

 

100%

Group net sales amounted to € 19,687 million in fiscal 2021 (2020: € 17,534 million). As in the previous year, around 4% of this figure was recognized over time (2021: € 726 million; 2020: € 697 million). This mainly related to net sales from services and from customer-specific equipment in the Applied Solutions and Process Solutions business units in the Life Science business sector and net sales from the project business of the Semiconductor Solutions business unit in the Electronics business sector.

The table below shows future net sales from orders already received:

 

 

Year of expected revenue recognition

€ million

 

2022

 

2023 or later fiscal years

 

Total

As of Dec. 31, 2021

 

5,729

 

364

 

6,093

 

 

Year of expected revenue recognition

€ million

 

2021

 

2022 or later fiscal years

 

Total

As of Dec. 31, 2020

 

3,892

 

376

 

4,268

The significant increase as against the previous year resulted, in particular, from the positive performance of the Process Solutions business unit in the Life Science business sector.

The following table shows the change in refund liabilities:

2020

 

 

Rebates/Bonus payments

 

Rights of return

 

 

€ million

 

Total

 

thereof: United States

 

Total

 

thereof: United States

 

Total

Jan. 1, 2020

 

522

 

315

 

43

 

29

 

565

Additions due to business combinations

 

 

 

 

 

Other additions

 

1,713

 

1,234

 

41

 

20

 

1,754

Disposals due to divestments/Reclassification to assets held for sale

 

-8

 

 

 

 

-8

Utilizations

 

-1,501

 

-1,081

 

-33

 

-17

 

-1,534

Cumulative increase (-)/decrease (+) in net sales

 

-66

 

-67

 

-3

 

-4

 

-69

thereof: attributable to performance obligations satisfied in prior periods

 

-48

 

-48

 

-3

 

-3

 

-51

Currency translation

 

-39

 

-35

 

-4

 

-3

 

-42

Other

 

1

 

 

 

 

1

Dec. 31, 2020

 

622

 

368

 

44

 

26

 

666

2021

 

 

Rebates/Bonus payments

 

Rights of return

 

 

€ million

 

Total

 

thereof:
United States

 

Total

 

thereof:
United States

 

Total

Jan. 1, 2021

 

622

 

368

 

44

 

26

 

666

Additions due to business combinations

 

 

 

 

 

Other additions

 

2,216

 

1,528

 

58

 

34

 

2,273

Disposals due to divestments/Reclassification to assets held for sale

 

 

 

 

 

Utilizations

 

-1,995

 

-1,392

 

-48

 

-27

 

-2,044

Cumulative increase (-)/decrease (+) in net sales

 

-102

 

-94

 

-2

 

-1

 

-105

thereof: attributable to performance obligations satisfied in prior periods

 

-86

 

-82

 

2

 

2

 

-83

Currency translation

 

43

 

35

 

3

 

3

 

47

Other

 

1

 

 

 

 

1

Dec. 31, 2021

 

784

 

445

 

55

 

35

 

839

The development in contract assets and contract liabilities is shown in Note (26) “Contract assets” and in Note (29) “Other non-financial liabilities”.

Share this page: